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ABSTRACT 
In the past few decades, the field of acute ischemic stroke (AIS) has experienced significant 
advances in clinical practice.  A core driver of this success has been the utilization of acute 
stroke imaging with an increasing focus on advanced methods including multimodal imaging.  
Such imaging techniques not only provide a richer understanding of AIS in vivo, but also, in 
doing so, provide better informed clinical assessments in management and treatment toward 
achieving best outcomes.  As a result, advanced stroke imaging methods are now a mainstay of 
routine AIS practice that reflect best-practice delivery of care.  Furthermore, these imaging 
methods hold great potential to continue to advance the understanding of AIS and its care in 
the future. 
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INTRODUCTION 
Over the past few decades, the field of acute ischemic stroke (AIS) has made landmark strides in 
routine care.  Pivotal to this advancement has been the incorporation and utilization of 
advanced neuroimaging, which has afforded stroke care providers a significant improvement in 
understanding of AIS pathophysiology and identification of its subclassifications toward better 
informed therapeutic decision-making and resultant outcomes.  As a consequence, acute stroke 
multimodal imaging methods are now recognized as an essential component of empirically-
based, best-practice delivery of AIS care1,2. Furthermore, because of its now firmly established 
impact on and foothold within AIS management, advanced stroke imaging has positioned itself 
as a continued prime player in the field’s ongoing goal to reduce barriers to treatment and 
facilitate success in outcomes.  
In this review, we address advanced acute stroke imaging’s powerful ability to rapidly and 
accurately profile, understand, and characterize AIS pathophysiology; its crucial role in AIS 
routine practice currently; and the potential for its novel applications to continue to shape and 
advance the field of AIS in the future. 
PATHOPHYSIOLOGY OF AIS 
An understanding of cerebrovascular hemodynamics and stroke pathophysiology is essential to 
the interpretation and application of information that acute stroke imaging provides. Cerebral 
perfusion pressure (CPP) is equal to mean arterial pressure (MAP) minus intracranial pressure 
(ICP) (Equation 1). In ischemic stroke, sustained increases in ICP (from cytotoxic edema) or 
sudden drops in MAP (from arterial occlusion) can lead to a reduction in CPP. The protective 
mechanism of cerebrovascular autoregulation helps maintain a constant cerebral blood flow 
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(CBF) over a wide CPP range by altering the caliber of cerebral arterioles (Figure 1). Thus, CBF is 
defined as CPP divided by cerebrovascular resistance (CVR) (Equation 2). 
Equation 1: CPP = MAP – ICP 
Equation 2: CBF = CPP / CVR   
AIS has historically been classified into three distinct stages of cerebral hemodynamics. In stage 
I of an ischemic event, the cerebrovascular system labors to maintain a constant CBF in the face 
of low CPP through vasodilation of cerebral arterioles and recruitment of collateral 
cerebrovascular supply.  At this stage, despite stress on the affected cerebrovascular territory, 
compromise and resultant ischemia of its supplied territory is avoided, theoretically 
indefinitely.  However, as the limits of autoregulation are reached and CBF nears the critical 
ischemic threshold, the cerebrovascular system enters stage II of AIS in which hemodynamic 
failure and increase of oxygen extraction occur. During this stage, the cerebral tissue is at risk of 
infarction if reperfusion is not achieved promptly. This area of potentially salvageable tissue is 
termed the ischemic penumbra. With further reductions in CBF, failure of the collateral 
cerebrovascular supply follows, causing oxygen extraction to wane and become no longer 
sufficient to maintain tissue metabolism: thus, irreversible injury and cell death (ischemic core) 
result.  
Although AIS revascularization therapies have been well established to improve outcomes on a 
population basis, a significant proportion of patients treated within established timeframes of 
eligibility unfortunately do not reap significant functional improvement3.  On a patient level, 
these effects are likely attenuated and/or negated because these time windows of symptom 
duration do not adequately account for variations in individual cerebrovascular anatomy, 
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cerebral autoregulation reserve, and collateral cerebrovascular supply and status. Cerebral 
collateral circulation helps stem expansion of infarct core volume via shunting the blood supply 
around an arterial occlusion through alternative arterial pathways, thereby maintaining 
adequate CBF to the affected field of tissue.  Stroke severity and rate of ischemic injury 
progression is largely dependent upon a complex interplay between, among others, robustness 
of collateral circulation, the CBF nadir, and chronic disease states, such as chronic hypertension, 
which can shift the limits of autoregulation4. For example, for a given affected territory, a 
patient with low CBF and poor baseline collateral anatomy and/or status will likely more quickly 
”complete” conversion from penumbra to ischemic core than, for example, a patient with 
higher CBF and good baseline collateral anatomy and/or status5.  
PRESENT APPLICATIONS OF ACUTE STROKE IMAGING 
The goal of acute stroke imaging is to provide a rapid, accurate snapshot of acute brain and 
cerebrovascular pathology to determine which patients are most likely to be favorable 
candidates for and responders to revascularization therapies such as intravenous (IV) tissue 
plasminogen activator (tPA) and endovascular revascularization therapies (ERT). Brain imaging, 
traditionally and most commonly with non-contrast head CT, plays an essential role in AIS 
treatment selection and eligibility determination.  For one, it is the only imaging modality 
required for determination of eligibility for IV tPA administration. Its main role is to exclude 
radiographic contraindications to IV tPA: namely, intracranial hemorrhage, large ischemic 
strokes (> 1/3 of the middle cerebral artery (MCA) territory), and structural lesions such as 
tumors6,7.  Despite the fact that CT has low sensitivity (42-63%) for detection of acute and small 
ischemic infarcts, especially in the posterior fossa8, its rapid acquisition time, relative ease of 
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identification of hemorrhage by non-radiologists, and widespread availability in the community 
make CT the recommended imaging modality in the time sensitive evaluation for IV tPA9. 
Even though CT is the clear modality of choice in routine practice, MRI is utilized at some 
centers as the first-line brain imaging method.  MR imaging holds a few key advantages over 
CT-based brain imaging in AIS care.  For one, diffusion-weighted imaging (DWI) offers superior 
sensitivity and specificity over CT in AIS detection. DWI abnormalities appear within minutes 
after ischemia occurs, and may be detected in as many as 96.1 – 99.6% of patients when 
performed within 6 hours of the onset10. Moreover, through multiple different imaging 
sequences (fluid attenuated inversion recovery (FLAIR); gradient echo (GRE); and T2-weighted 
sequences)11, MRI provides more information about ischemia-associated lesions that CT cannot 
offer: high resolution and accuracy of location and pattern, chronicity, and 
ischemic/hemorrhagic components, all of which lend additional diagnostic power towards 
assessment and understanding of lesion etiology. While MRI can offer enhanced diagnostic 
power to the stroke provider and thus improved ability to guide AIS treatment, it has a few 
important disadvantages in comparison to non-contrast CT that have limited its widespread 
adoption; mainly, its use is often considered more time- and cost-prohibitive. For one, most 
centers’ MR facilities are not typically physically located near the ED triage area, thus delaying 
expedient completion.  Additionally, costs associated with MR facility maintenance and 
operation often may prove unjustifiable for around-the-clock availability, especially in centers 
of care where MRI may not be commonly utilized such as in rural communities or in areas of 
low-population density.  Furthermore, unlike CT, MRI requires safety screening and patient 
consent, which may lend to additional impediments and delays to timely completion, especially 
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in select AIS sub-populations (e.g. those with aphasia, neglect, or impaired consciousness).  
Lastly, although MRI holds greater diagnostic power than CT in AIS management, it requires 
greater knowledge and familiarity with a wider range of aforementioned imaging sequences, 
and thus its diagnostic application often necessitates input from radiologists.   
In addition to evaluating for such exclusions to tPA like acute hemorrhage, brain imaging also 
enables stroke care providers to predict safety and efficacy of AIS treatment at a patient level.  
For one, early infarct core size holds key prognostic value for treatment decision-making12. This 
has resulted in its increasingly more commonplace use in routine practice, including through 
incorporation of formal scoring metrics such as the Alberta Stroke Program Early CT Score 
(ASPECTS).  ASPECTS is an empirically validated, 10-point systematic method for evaluation of 
early ischemia within the anterior circulation on non-contrast brain CT (Figure 2). The 
parenchymal field subserved by the vascular territories of the anterior fossa is divided into 10 
distinct regions, each of which is assessed and graded for early ischemic changes as defined by 
relative hypodensity.  From this tabulation, a composite score from 10 (no ischemia) to 0 
(ischemia of entire field) is generated that provides a rapid assessment of ischemic burden 
within the anterior vascular field, and consequently, prognosis for AIS treatment decision-
making through its identification of candidates most likely to respond clinically favorably 
(ASPECTS ≥6) to or to suffer complications from revascularization therapies1,13. In addition to its 
well-established value in AIS care, another key advantage of ASPECTS is that it requires only 
basic familiarity with CT interpretation and the ASPECTS scoring methodology.  Therefore, its 
powerful utility and ease of use encourages its readied adoption and use throughout the stroke 
care community at specialized and unspecialized centers alike.   
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In addition to providing critical information about status of parenchymal tissue, noncontrast 
brain CT also holds diagnostic utility in evaluation of vessel pathology in acute stroke care: the 
hyperdense thrombosed large-vessel sign.  Visible as increased density, most classically in linear 
form for an affected proximal MCA vessel, the sign is highly suggestive of a large-vessel 
occlusion (LVO) within the proper clinical context of an acute stroke syndrome attributable to 
occlusion of that vessel.  This sign is seen in approximately only one-third of angiographically 
confirmed LVOs14,15.  Therefore, although its detection may provide guidance for treatment 
decision-making, its absence does not permit such guidance. 
While brain imaging has been a mainstay of AIS care for over two decades, acute stroke 
multimodal imaging has materialized as a necessary component of routine care only in the past 
few years.  The success of the multiple, recent ERT trials which relied on cerebrovascular 
angiographic imaging for determination of AIS treatment eligibility within expanded time 
windows legitimized the necessity and paved the way for this radical update of imaging used in 
routine care.  Their landmark achievement firmly established that the incorporation of such 
imaging methods into AIS care provides not only a further enhanced profiling of acute stroke 
pathophysiology through rapid detection and assessment of thrombotic clot burden and 
location1, the presence of other vascular lesions (e.g., cerebral aneurysms, vascular 
malformations), and collateral vasculature status, but also, as a result, a powerful imaging-
based strategy of management that enhances eligibility for therapy as well as prognosis.   
The cerebrovascular imaging modality of choice is CT angiography (CTA) because of its wide 
availability, rapid acquisition time, and high sensitivity and specificity for LVO detection16. Of 
note, CTA carries a risk, although small and of unestablished significance, of contrast-related 
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nephropathy17-19, particularly among patients with pre-existing impairment of renal function.  
Magnetic Resonance Angiography (MRA) is another choice used as a first-line option at some 
centers; it has lower sensitivity but comparable specificity to CTA16.   Common MRA techniques 
include 2-dimensional time of flight (TOF), 3-dimensional TOF, and gadolinium-enhanced MRA. 
The gadolinium-enhanced technique allows improved visualization of distal vessels, and is less 
susceptible to motion artifacts.  The non-enhanced TOF, though more susceptible to motion 
artifact, may be preferred in patients with baseline kidney disease who are at risk for 
complications related to gadolinium exposure including, most seriously, nephrogenic systemic 
fibrosis.  While TOF MRA is helpful in identifying proximal LVOs, it is not considered as reliable 
for detection of distal vessel occlusions20. 
The 2015 update of the American Heart Association (AHA)/American Stroke Association (ASA) 
guidelines reflects the advent of advanced imaging as standard of care when considering 
endovascular treatment options for patients with AIS1. Multimodal imaging, in the form of 
ASPECTS scores as well as evidence of large vessel occlusion on CT angiogram, was a critical 
feature leading to the overall success of the endovascular trials (Table 1). Despite some 
variation in selection criteria for the different trials mainly regarding the minimum eligible 
NIHSS score and also the timeframe for inclusion, the use of more refined imaging tactics 
allowed for improved selection of patients who were more likely to have a beneficial response 
to endovascular intervention. The available data from the aforementioned studies led to the 
recommendation that endovascular intervention should be considered for patients who 
present with NIHSS and ASPECTS scores greater than 6 and an imaging-confirmed internal 
carotid artery (ICA) or MCA large-vessel (M1) occlusion within 6 hours from symptom onset. 
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In the wake of these recent advances and the AHA/ASA recommendations that were based 
upon them, treatment centers have begun to update their acute stroke imaging protocols to 
reflect these new standards in stroke care.  As an illustrative example, a typical acute stroke 
imaging pathway for patients presenting to a comprehensive stroke center with stroke 
symptoms suggestive of a LVO syndrome within 6 hours is presented in Case 1 and Figure 3.  
FUTURE APPLICATIONS OF ACUTE STROKE IMAGING 
The currently accepted model of AIS considers both the ischemic core and penumbra of an 
affected vascular territory as essential to the profile of AIS in vivo.  Because it is at risk, but still 
viable tissue, the penumbra is the prime target of salvage for all revascularization therapies21.  
Perfusion imaging modalities (CT and MR perfusion) allow estimation of penumbral volume 
through assessment of cerebral hemodynamics by tracking the flow of contrast within a region 
of interest, and generating qualitatively informative maps for CBF, Cerebral Blood Volume 
(CBV), Mean Transit Time (MTT) and Time to Peak (TTP). These maps may in turn be used to 
estimate the volume of the ischemic core and ischemic penumbra (Table 2).    
Not surprisingly, because of its unique capability to provide penumbral status in AIS, perfusion-
based imaging is considered to hold great potential in the continued advancement of AIS care.  
Integration of such advanced imaging methods into acute stroke imaging further refines the 
profile of AIS through an assessment that reflects within an affected cerebrovascular territory 
not only ischemic status (e.g. ASPECTS of non-contrast head CT) and thus infarcted tissue which 
reduces candidacy for treatment, but also of penumbral status and thus tissue which may 
respond best to it.  As a result, perfusion-based acute stroke imaging theoretically allows the 
provider to depend less strictly in absolute terms on time/duration of symptoms: a potential 
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key to further reduce time-based restrictions to and improve outcomes from treatments22.  
Although not yet evidence-based, some stroke centers have already incorporated perfusion 
imaging into their acute stroke imaging protocol, and may employ such a hypothetical pathway 
for identifying AIS candidates for treatment who present beyond 6 hours from symptom onset 
(figure 4). 
In line with this rationale of use by some centers, the ability to translate perfusion-based 
imaging’s unique assessment of salvageable tissue status into improved outcomes is currently 
under investigation23.   Studies using perfusion-based techniques have already provided 
demonstration that profiles reflecting a small infarct core to large penumbra ratio are 
considered the most likely to respond favorably to reperfusion therapies24,25. The concept of 
perfusion-guided intervention in extended time windows is currently under investigation for 
both IV tPA and ERT (Case 2 and Table 3). Both the European cooperative acute stroke study-4: 
Extending the time for thrombolysis in emergency neurological deficits (ECASS:4 ExTEND)26 and 
the multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate 
EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND)27 trials are 
testing the utility of perfusion imaging for an extended time window for IV tPA (up to 9 hours).  
Because it has been shown that ischemic penumbra may be present up to 24 hours in AIS28, 
great interest has focused on expanding allowed time windows of treatment even further: the 
Endovascular therapy following imaging evaluation for ischemic stroke 3 (DEFUSE 3)23, 
Perfusion Imaging Selection Of Ischemic Stroke Patients For Endovascular Therapy (POSITIVE)29 
and the Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing 
Neurointervention With Trevo (DAWN)30 trials are evaluating the use of angiography (CT or MR-
13 
 
based) in combination with perfusion-based techniques for treatment up to 24 hours after 
symptom onset.  Although inclusion criteria and perfusion parameters vary between these 
trials, their a priori requisite assessment of a favorable penumbra/core volume ratio for 
determination of treatment candidacy is shared by them all. 
 Although of currently unknown clinical utility, arterial spin labeled MRI (ASL) is another 
emerging perfusion imaging method which holds exciting implications for potential application 
in AIS2,31. This technique assesses diffusion of arterial water to generate a CBF map, and thus 
estimate ischemic penumbra.  A major advantage of ASL is that it requires no IV contrast, which 
makes its validation highly attractive as an imaging application that may enhance care without 
compromise of safety (FIGURE 5). 
As AIS investigations utilizing perfusion-based imaging continue to improve understanding of 
the ischemic penumbra and its relationship with and transition to the ischemic core, an 
improved and more accurate profiling of the AIS pathophysiology will hopefully follow towards 
achievement of the stroke community’s ultimate goal: care both freed from the restrictions of 
time and that optimizes chances for best outcomes. 
TRANSITION FROM CT TO MR ACUTE STROKE IMAGING 
Although CT-based imaging has been the cornerstone of advanced imaging within acute stroke 
and its improvement in care, MR based methods provide even greater promise for potential 
advances in AIS care. Not only is its sensitivity and specificity for detection of ischemia superior 
to CT-based methods10, but also MR-based methods are acquired in equitably rapid fashion32 
with reduced risk exposure.  Hence, utilization of MR-based acute stroke imaging may prove to 
further AIS care in a variety of ways: refining diagnosis and thus increasing treatment rates, as 
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well as mitigating unnecessary imaging and treatment exposure. For instance, implementation 
of rapid MRI32 protocols in routine AIS care may better identify ischemic events masquerading 
as non-ischemic ones and exclude non-ischemic ones mimicking ischemic ones.  
CONCLUSION 
Advanced stroke imaging has established itself as an integral component of AIS practice.  
Multimodal imaging methods afford an enriched understanding of acute stroke 
pathophysiology that empowers providers to deliver stroke care that reflects standards of care 
aimed at achievement of best outcomes.  Advanced stroke imaging will likely continue to be a 
driver of the ever-evolving field of AIS: one highlighted by less barriers to, and more successes 
from, treatment. 
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Figure 1: Cerebrovascular Autoregulation: relationships between vascular caliber and 
intracranial pressure on cerebral perfusion pressure and cerebral blood flow 
Reprinted with permission from Rose JC, Mayer SA. Optimizing blood pressure in neurological 
emergencies. Neurocrit Care. 2006;4(1):98-98 
 
Figure 2: Alberta Stroke Program Early CT (ASPECT) Score  
(A) Axial CT image at the level of basal ganglia and thalamus. (B) Axial CT image at 
supraganglionic level above the level of lateral ventricles 
 
Figure 3: Acute stroke imaging pathway for evaluation of patients presenting within 6 hours 
of symptom onset.  
 
Figure 4: Acute stroke imaging pathway integrating CT perfusion 
 
Figure 5: Arterial Spin Labeled-MRI 
Patient who presented with an acute right middle cerebral artery occlusion, out of the 
conventional 6 hour therapeutic window. CT perfusion (MTT and Tmax) shows an area of 
hypoperfusion in the right hemisphere which corresponds to the hypoperfused area on the 
Arterial Spin Labeled MRI done 24 hours later. MTT: Mean Transit Time; Tmax: Time-to-
Maximum; ASL: Arterial Spin Labeled 
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Case 1 
A 70-year-old man with atrial fibrillation was brought to the emergency room with acute onset 
of left sided weakness, left hemineglect and a right gaze preference (NIHSS 16).  He was last 
seen well five hours prior to arrival to the ER.  CT of the head shows a hyperdense right MCA 
vessel (arrow) and an ASPECTS score of 5 (hypodensities in frontal, parietal and insular regions). 
Given these findings, the patient was determined to be a poor candidate for acute treatment.  
 
Case 2:  
A 54-year-old man presents with word-finding difficulty and left hemiparesis (NIHSS 7) that was 
discovered upon awakening from sleep. He was last seen normal the night prior to 
presentation. CT of the head showed an ASPECTS score of 10.  
(A) CT angiogram showed occlusion in left ICA terminus (blue arrow) with good collaterals. (B) 
Cerebral blood volume map showing no large ischemic core. (C) Increased mean transit time in 
left hemisphere suggestive of large mismatch/penumbra. (D) Conventional angiogram showing 
left ICA terminus occlusion. The patient was determined to be a favorable candidate for 
endovascular therapy, and underwent revascularization with subsequent rapid clinical 
improvement.  (E) Post-thrombectomy with revascularization. (F) MRI brain DWI sequence 24 
hours after thrombectomy showing a small periventricular infarct  
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Table 1: Imaging Criteria of the Recent Endovascular Trials 
 Vessel 
Imaging 
Occluded 
Vessel 
ASPECT Perfusion 
Imaging 
Symptoms 
onset 
Outcomea  
MR CLEAN MRA, CTA or 
DSA 
Distal ICA, 
M1, M2, A1 
or A2 
Not 
used 
Not used < 6 hours 32.6% vs. 
19.1% 
EXTEND IA MRA, CTA or 
DSA 
ICA, M1 or 
M2 
Not 
used 
bMismatch 
ratio > 1.2, 
ischemic core 
volume < 70 
mL 
< 6 hours 71% vs. 
40%  
THRACE CTA or MRA ICA, M1 or 
the superior 
1/3 of the 
basilar artery 
Not 
used 
Not used < 5 hours 53% vs 
42% 
SWIFT 
PRIME 
CTA or MRA ICA, M1 or 
M2 
> 6 Mismatch 
ratio 1.2 – 1.8 
and a small 
core of infarctc 
< 6 hours 60% vs. 
35% 
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REVASCAT CTA or MRA  ICA or M1  > 7 on 
CT 
> 6 on 
DWI 
Not used < 8 hours 43.7% vs. 
28.2% 
ESCAPE CTA with 
scoring of 
collateralsd 
ICA, M1 or 
M2 
> 6 Not used < 12 hours 53.0%, vs. 
29.3% 
CTA= Computed Tomography Angiography; MRA= Magnetic Resonance Angiography; DSA= 
Digital Subtraction Angiography; DWI= Diffusion-Weighted Imaging 
a Modified Rankin Score 0-2 at 90 days, treatment vs. control groups. 
b Perfusion assessed with an automated reading software (RAPID). Hypoperfusion was defined 
as Tmax > 6 seconds. Ischemic core diagnosed as relatively cerebral blood flow < 30% of normal 
tissue or by DWI volume. 
c Infarct less than 1/3 of the MCA territory on CT or DWI, or > 100 cc in other territories. Severe 
hypoperfusion (Tmax > 10 sec) < 100 cc.  
dModerate-to good collateral circulation was defined as the filling of 50% or more of the middle 
cerebral artery by pial arterial circulation on CTA 
 
Table 2: CT Perfusion definitions 
 CBV CBF MTT 
Definition Volume of blood present 
in brain parenchyma 
Rate of blood flow 
through brain 
Time needed for blood to 
transit through brain 
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parenchyma parenchyma 
Core ↓ ↓↓ ↑ 
Penumbra ↔/↑ ↓ ↑ 
 
 
Table 3: Ongoing Trials Using Perfusion Imaging to Expand the Treatment Window 
 Intervention 
type 
Stroke onset / 
Last known 
normal 
Imaging Modalities Imaging Criteria 
ECASS-4: 
ExTEND26 
IV tPA 4.5 – 9 hours MRI with PWI PWI:DWI ratio of 
1.2.Infarct core < 1/3 
of the MCA territory 
or < 100 mL 
EXTEND27 IV tPA 4.5 – 9 hour CT, CTP, MRI with 
PWI 
PWI:DWI ratio of 1.2. 
Infarct core <70 mL 
DEFUSE 323 ERT 6 – 16 hours CT, CTA, CTP, MRI, 
MRA, PWI 
ICA or M1 occlusion; 
target mismatcha 
POSITIVE29 ERT 6 – 12 hours CT, CTA, CTP, MRI, 
MRA, PWI 
ICA or M1 
DAWN30  ERT 6 – 24 hours CT, CTP, MRI, PWI, 
CTA, MRA 
ICA or M1 occlusion, 
Mismatch on MR-DWI 
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or CTPb 
MRI= Magnetic Resonance Imaging; PWI= Perfusion-Weighted Imaging; CTP= Computed 
Tomography Perfusion; IV tPA= Intravenous Recombinant Plasminogen Activator (ALTEPLASE); 
ERT= Endovascular Recanalization Therapy 
